Grino 1991.

Methods	Study design: parallel RCT Study duration: March 1988 to December 1990 Study follow‐up: 2 years
Participants	Country: Spain Setting: single centre Inclusion criteria: 1st DD kidney transplant recipients Number: treatment group 1 (68); treatment group 2 (72) Mean age ± SD (years): treatment group 1 (42.6 ± 13); treatment group 2 (39 ± 11) Sex (M): treatment group 1 (59%); treatment group 2 (57%) Exclusion criteria: not reported
Interventions	Treatment group 1 Horse ALG: 15 mg/kg pre‐transplant, 12 mg/kg day 1, then 10 mg/kg alternate days for 4 doses Dose adjusted to maintain CD3 counts 10% to 20% Treatment group 2 OKT3: 5mg IV at induction, continued daily for 5 doses total Immunosuppression (both groups) MP: 1 mg/kg in operating theatre, then 0.25 mg/kg, then taper to 0.1 mg/kg CSA: 3 mg/kg IV pre‐op, then 3 mg/kg in 2 doses post‐op, then oral 8 mg/kg in 2 doses
Outcomes	Death Graft loss DGF Acute rejection Serious infection
Notes	Funding source: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Low risk	"randomly allocated by a closed‐envelope technique"
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Unlikely to influence outcomes
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Unlikely to influence outcomes
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patient outcome data reported
Selective reporting (reporting bias)	Low risk	All expected outcomes reported
Other bias	Unclear risk	Funding source not reported